Literature DB >> 9133522

High-dose heparin decreases nitric oxide production by cultured bovine endothelial cells.

G R Upchurch1, G N Welch, J E Freedman, A J Fabian, A Pigazzi, A M Scribner, C S Alpert, J F Keaney, J Loscalzo.   

Abstract

BACKGROUND: Abrupt cessation of heparin therapy can lead to a recrudescence of thrombosis and acute ischemia. Endothelial NO is an important endogenous inhibitor of platelet-mediated thrombosis, yet biochemical studies examining the effect of heparin on NO production by the endothelium have heretofore been lacking. METHODS AND
RESULTS: In an attempt to address the effect of heparin on endothelial cell production of NO, confluent bovine aortic endothelial cells (BAECs) on microcarrier beads were incubated in the presence or absence of heparin. Results indicate that BAECs incubated with heparin were less able to inhibit platelet aggregation than control cells (P<.005 by ANOVA) and that this effect correlated with a decrease in NO production (36% decrease for heparin compared with control, P<.05). Dextran sulfate evoked the same response (67% decrease, P<.0001 compared with control), suggesting that the decrease in NO after heparin treatment is secondary to its negative charge rather than to a specific polysaccharide sequence. The decrease in NO production by heparin was accompanied by a 72% decrease in steady-state Nos 3 mRNA as well as a 49% decrease in immunodetectable endothelial NO synthase (eNOS) protein.
CONCLUSIONS: These data show that high-dose heparin at concentrations achieved in some acute cardiovascular settings increases in vitro platelet aggregation in media conditioned by endothelial cells by decreasing endothelial NO production through a mechanism that involves a decrease in steady-state Nos 3 mRNA and eNOS protein. These observations suggest a possible mechanism by which to explain in part the prothrombotic effects of heparin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133522     DOI: 10.1161/01.cir.95.8.2115

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  4 in total

1.  Role of PGI2 in the formation and maintenance of hyperdynamic circulatory state of portal hypertensive rats.

Authors:  Zhi-Yong Wu; Xue-Song Chen; Jiang-Feng Qiu; Hui Cao
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

2.  CD34+ circulating cells display signs of immune activation in patients with acute coronary syndrome.

Authors:  Lisa Riesinger; Michael Saemisch; Markus Nickmann; Heiko Methe
Journal:  Heart Vessels       Date:  2018-07-12       Impact factor: 2.037

3.  Pentadecapeptide BPC 157 Reduces Bleeding and Thrombocytopenia after Amputation in Rats Treated with Heparin, Warfarin, L-NAME and L-Arginine.

Authors:  Mirjana Stupnisek; Antonio Kokot; Domagoj Drmic; Masa Hrelec Patrlj; Anita Zenko Sever; Danijela Kolenc; Bozo Radic; Jelena Suran; Davor Bojic; Aleksandar Vcev; Sven Seiwerth; Predrag Sikiric
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

4.  Heparanase inhibition preserves the endothelial glycocalyx in lung grafts and improves lung preservation and transplant outcomes.

Authors:  Kentaro Noda; Brian J Philips; Mark E Snyder; Julie A Phillippi; Mara Sullivan; Donna B Stolz; Xi Ren; James D Luketich; Pablo G Sanchez
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.